首页> 中文期刊> 《中国药理学与毒理学杂志》 >Inflammation and dysregulation of immune response in Alzheimer disease, the drug target for the future

Inflammation and dysregulation of immune response in Alzheimer disease, the drug target for the future

         

摘要

It has been demonstrated that inflammation and dysregulation of immune response are involved in the pathogenesis of Alzheimer disease (AD). Inflammation is an early event in AD development, especially inflammasome and pro-inflammatory molecules are pathogenic factor in AD. Our data showed that activated immune cells may contribute to the pathogenesis of AD, since the mice with immune cells knock out demonstrated differentsings in the neurodegenerative process and T cells aid clearance of plaques in mice and infiltrating parenchymal T-cell in AD brain mainly in the light of amyloid pathology, and immune treatment is effective, etc. However, the direct evidence on T and B cells infiltrating into the brain of APP transgenic mice have not yet found. Whether aged T cells are pathogenic in AD?How is role of aged B cells? These questions are still unclear. In conclusion, activated immune cells,and inflammatory molecules may play important roles in neurodegenerative disorders, such as AD. The mechanisms of behind this are needed to further study. Inhibiting inflammation in the early phase of AD and restore normal immune regulation are new drug target for the future.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号